Scientific Research News

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swel...

DAVIS, Calif.--(BUSINESS WIRE)--BioConsortia Receives $15 Million in New Funding for New Microbial Product Launches for Sustainable Agriculture....

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress...

SAN ANTONIO--(BUSINESS WIRE)--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules...

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Northwell Health’s Center for Gun Violence Prevention has developed a proven approach to firearm injury prevention, and now, with a $650,000, one-year research grant from the Centers for Disease Control and Prevention (CDC), the health system is expanding that work with a focused lens on women’s health. The grant will fund a new study integrating the health system’s universal firearm safety screening and education into routine women’s health care, bringing...

TORONTO--(BUSINESS WIRE)--BetterUp Canada Inc., the Canadian operations of BetterUp®, the human transformation company and pioneer of virtual coaching, today announced The Ontario Frontline Study, a first-of-its-kind research program centred on first responders and healthcare workers. The research effort is a multi-year study that aims to explore whether and how personalized coaching can build resilience, reduce stress, and improve overall well-being for these workers, who operate in immensely...